Citizens' preferences for brand name drugs for treating acute and chronic conditions: a pilot study.

Background: Generic drugs have been advocated to decrease the proportion of healthcare costs devoted to drugs, but are still underused. Objective: To assess citizens' preferences for brand name drugs (BNDs) compared with generic drugs for treating acute and chronic conditions. Methods: A questionnaire with eight hypothetical scenarios describing four acute and four chronic conditions was developed, with willingness to pay (WTP) determined using a payment card system randomized to ascending (AO) or descending order (DO) of prices. The questionnaire was distributed with an explanation sheet, an informed consent form and a pre-stamped envelope over a period of 3 weeks in 19 community pharmacies in Lausanne, Switzerland. The questionnaire was distributed to every third customer who also had health insurance, understood French and was aged =16 years (up to a maximum of ten customers per day and 100 per pharmacy). The main outcome measure was preferences assessed by WTP for BNDs as compared with generics, and impact of participants' characteristics on WTP. Results: Of the 1800 questionnaires, 991 were distributed and 393 returned (pharmacy participation rate?=?55%, subject participation rate?=?40%, overall response rate?=?22%); 51.7% were AO and 48.3% DO. Participants were predominantly women (62.6%) and of median age 62 years (range 16-90). The majority (70%) declared no WTP for BNDs as compared with generics. WTP was higher in people with an acute disease than in those with a chronic disease, did not depend on the type of chronic disease, and was higher in people from countries other than Switzerland. Conclusions: Most citizens visiting pharmacies attribute no added value to BNDs as compared with generics, although some citizen characteristics affected WTP. These results could be of interest to several categories of decision makers within the healthcare system.

Theoretical approach to the magnetostructural correlations in spin-Peierls compound CuGeO3

A theoretical density-functional study has been carried out to analyze the exchange coupling in the chains of CuGeO3 using discrete models. The results show a good agreement with the experimental exchange coupling constant (J) together with a strong dependence of J with the Cu-O-Cu angle. The calculation of the J values for a distorted model indicates a larger degree of dimerization than those reported previously.

High-Temperature magnetic ordering in a new organic magnet

Magnetization, heat capacity, and neutron diffraction experiments on the beta-phase of the dithiadiazolyl radical, p-NC.C6F4.CNSSN., provide conclusive evidence that this system exhibits noncollinear antiferromagnetism at 35.5 K, an unprecedented temperature for an organic radical. On the basis of magnetization and powder neutron diffraction results, coupled with theoretical calculations of the spin distribution within the molecule, a magnetic structure for this compound is proposed in which the interactions propagate through S . . .N contacts.

Theoretical approach to the magnetostructural correlations in spin-Peierls compound CuGeO3

A theoretical density-functional study has been carried out to analyze the exchange coupling in the chains of CuGeO3 using discrete models. The results show a good agreement with the experimental exchange coupling constant (J) together with a strong dependence of J with the Cu-O-Cu angle. The calculation of the J values for a distorted model indicates a larger degree of dimerization than those reported previously.

Do youths gamble? You bet! A Swiss population-based study

Cette recherche sur les jeux d'argent et de hasard au sein de la population des jeunes résidents Suisses avait trois objectifs. Pour avoir des données de base, nous nous sommes d'une part intéressés à la prévalence de ce comportement et, basé sur des critères de fréquence, avons mis en évidence une population plus à risque de subir des conséquences néfastes du jeu;à savoir ceux qui jouent au minimum une fois par semaine. Le deuxième objectif était de déterminer s'il existait une association entre la fréquence du jeu et 1) l'utilisation de substances, 2) une mauvaise santé mentale et/ou 3) un faible support social, comme cela a été décrit dans la littérature pour les joueurs pathologiques. Finalement, pour savoir si les joueurs fréquents étaient «fixés» sur un seul type de jeu ou au contraire jouaient de manière non-sélective, nous avons effectué la corrélation entre la fréquence de jeu et le nombre de jeux différents dans lesquels les jeunes étaient impliqués.Pour ces analyses, nous avons utilisé la base de données de l'Enquête Suisse sur la Santé 2007, une étude transversale interrogeant des résidents suisses âgés de 15 ans ou plus. Cette enquête a été menée en deux étapes: 1) un questionnaire téléphonique (taux de réponse: 66.3%) puis 2) un questionnaire écrit (taux de réponse: 80.5% de ceux qui ont répondu à l'interview téléphonique). En tenant compte de la pondération pour l'échantillon de participants ayant répondu aux deux types d'interviews, nous avons considéré uniquement les personnes âgées de 15 à 24 ans. Au total 1116 (582 hommes) participants ont été retenus pour notre étude.Pour répondre au second objectif, nous avons comparé trois groupes. Les non-joueurs (NJ, n=577), les joueurs occasionnels (JO, n=388) et les joueurs fréquents (JF, n=151) ont été étudiés d'abord grâce à des analyses bivariées, puis à une régression multinomiale permettant de tenir compte des facteurs confondants. La sélection des variables pour la régression a été basée sur une méthode «bootstrap» permettant de produire des résultats représentatifs de la population entière et pas uniquement de l'échantillon analysé.Nous avons procédé de manière similaire pour répondre à la troisième question de recherche, mais en comparant uniquement les joueurs occasionnels et les joueurs fréquents.Les résultats ont mis en évidence que 48.3% des jeunes résidents suisses étaient impliqués dans au moins un type de jeu dans l'année précédente. Par ailleurs, 13.5% (n=151) des 15 à 24 ans jouaient au minimum une fois par semaine.Au niveau bivarié, la fréquence de jeu était associée à des facteurs sociodémographiques comme le sexe masculin, l'âge (les JO étant les plus âgés), et le revenu personnel. La fréquence de jeu était également significativement associée au fait de fumer du tabac quotidiennement, d'être actuellement fumeur de cannabis et d'avoir une consommation d'alcool à risque (beuveries). La mauvaise santé mentale (épisode de dépression majeure ou détresse psychologique) et le faible support relationnel (personne de confiance dans l'entourage ou activités de loisirs) n'étaient pas associés à la fréquence de jeu de manière significative, bien qu'une nette tendance en faveur des NJ ait pu être mise en évidence. Au niveau multivarié, les JO et JF étaient plus âgés, plus souvent de sexe masculin et habitaient plus souvent en Suisse romande que les NJ. Les JO étaient plus à risque que les NJ de se soumettre à des beuveries de manière occasionnelle et les JF étaient plus à risque que les NJ d'être des fumeurs de tabac quotidiens.En comparant les JO et les JF, nous avons obtenu une correlation élevée (r=0.85;p<0.0001) entre la fréquence de jeu et le nombre de jeux dans lesquels les jeunes étaient impliqués. Ceci indiquant que les JF ne semblent pas très sélectifs quant au type de jeu auquel ils jouent.Dans la mesure où le jeu est un comportement très prévalent au sein de la population des jeunes résidents suisses, il doit probablement être vu comme une conduite faisant partie des comportements exploratoires de l'adolescence. Néanmoins, au vu des comportements à risque qui y sont associés, la question du jeu devrait être soulevée par les médecins s'occupant de jeunes adultes à des fins de prévention.

Characterization of PhlG, a hydrolase that specifically degrades the antifungal compound 2,4-diacetylphloroglucinol in the biocontrol agent Pseudomonas fluorescens CHA0.

The potent antimicrobial compound 2,4-diacetylphloroglucinol (DAPG) is a major determinant of biocontrol activity of plant-beneficial Pseudomonas fluorescens CHA0 against root diseases caused by fungal pathogens. The DAPG biosynthetic locus harbors the phlG gene, the function of which has not been elucidated thus far. The phlG gene is located upstream of the phlACBD biosynthetic operon, between the phlF and phlH genes which encode pathway-specific regulators. In this study, we assigned a function to PhlG as a hydrolase specifically degrades DAPG to equimolar amounts of mildly toxic monoacetylphloroglucinol (MAPG) and acetate. DAPG added to cultures of a DAPG-negative DeltaphlA mutant of strain CHA0 was completely degraded, and MAPG was temporarily accumulated. In contrast, DAPG was not degraded in cultures of a DeltaphlA DeltaphlG double mutant. To confirm the enzymatic nature of PhlG in vitro, the protein was histidine tagged, overexpressed in Escherichia coli, and purified by affinity chromatography. Purified PhlG had a molecular mass of about 40 kDa and catalyzed the degradation of DAPG to MAPG. The enzyme had a kcat of 33 s(-1) and a Km of 140 microM at 30 degrees C and pH 7. The PhlG enzyme did not degrade other compounds with structures similar to DAPG, such as MAPG and triacetylphloroglucinol, suggesting strict substrate specificity. Interestingly, PhlG activity was strongly reduced by pyoluteorin, a further antifungal compound produced by the bacterium. Expression of phlG was not influenced by the substrate DAPG or the degradation product MAPG but was subject to positive control by the GacS/GacA two-component system and to negative control by the pathway-specific regulators PhlF and PhlH.

Canakinumab vs triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in "difficult to treat" gouty arthritis

Monosodium urate crystal deposition seen in gout stimulates IL-1 beta OR IL-1_; release. Canakinumab, a long-acting, fully human anti- IL-1 beta OR IL-1_; monoclonal antibody, effectively neutralizes IL-1 beta OR IL-1_;. Methods: This was an 8-week, dose-ranging, multi-center, blinded, doubledummy, active-controlled trial. Patients (aged 18-80 years) with an acute gout flare, refractory to or contraindicated to NSAlDs and/or colchicine, were randomized to one dose of canakinumab 10, 25, 50, 90, 150 mg s.c. or triamcinolone acetonide (TA) 40 mg i.m. Primary variable was assessed as pain intensity at 72 h post-dose (0-100 mm VAS). Secondary variables included pain intensity 24 and 48 h post-dose, time to 50% reduction in pain intensity, time to recurrence of gout flares up to 8 weeks post-dose, and rescue medication use. Results: 191/200 enrolled patients (canakinumab, n_143; TA, n_57) completed the study. Canakinumab showed significant dose-dependent pain reduction at 72 h. Canakinumab 150 mg showed superior pain relief versus TA starting from 24 h: estimated mean difference in pain intensity on VAS was -11.5 (24 h), -18.2 (48 h), and -19.2 (72 h) (all p_0.05). Canakinumab 150 mg provided a rapid onset of pain relief: median time to 50% reduction in pain was reached at 1 day with canakinumab 150 mg versus 2 days with TA (p_0.0006). At Week 8, recurrent flares occurred in 1 patient (3.7%) on canakinumab 150 mg versus 25 (44.6%) patients on TA (relative risk reduction, 94%; p_0.006). During 7 days post-dose, 6 patients (22.2%) on canakinumab 150 mg, and 31 patients (55.4%) on TA, took rescue medication. Time to first rescue medication was significantly longer with canakinumab 150 mg versus TA (hazard ratio, 0.36; p_0.02). Serious adverse events (canakinumab _lsqb_n_4_rsqb_ and TA _lsqb_n_1_rsqb_) were considered not treatment-related by investigators and no patient discontinued due to adverse events. Conclusions: Canakinumab 150 mg was well-tolerated, provided rapid and sustained pain relief in patients with acute gout flares, and significantly reduced the recurrent flare risk by 94% at 8-weeks post-dose compared with triamcinolone acetonide.

Canakinumab (ACZ885) vs triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in gouty arthritis patients refractory to or contraindicated to nsaids and/or colchicine.

Purpose: Current treatments for arthritis flares in gout (gouty arthritis) are not effective in all patients and may be contraindicated in many due to underlying comorbidities. Urate crystals activate the NALP 3 inflammasome which stimulate production of IL-1β, driving inflammatory processes. Targeted IL-1β blockade may be an alternative treatment for gouty arthritis. Canakinumab (ACZ885) is a fully human monoclonal anti- IL-1β antibody with a long half-life (28 days). Method: This was an 8-weeks, dose-ranging, multicenter, blinded, double-dummy, active-controlled trial of patients ≥18 to ≤80 y with an acute gouty arthritis flare, refractory to or contraindicated to NSAIDs and/or colchicine. Patients were randomized to 1 subcutanous (sc) dose of canakinumab (10, 25, 50, 90, or 150 mg) or 1 intra muscular (im) dose of triamcinolone acetonide (TA) [40 mg]. The primary variable was assessed 72 h post-dose, measured on a 0-100 mm VAS pain scale. Secondary variables included pain intensity 24 and 48 h post dose, time to 50% reduction in pain intensity, and time to recurrence of gout flares up to 8 weeks post dose. Results: 200 patients were enrolled (canakinumab n=143, TA n=57) and 191 completed the study. A statistically significant dose response was observed at 72 h. The 150 mg dose reached superior pain relief compared to TA starting from 24h: estimated mean difference in pain intensity on 0-100 mm VAS was -11.5 at 24 h, -18.2 at 48 h, and -19.2 at 72 h (all p<0.05). Canakinumab 150 mg provided a rapid onset of pain relief: median time to 50% reduction in pain was reached at 1 day with canakinumab 150 mg vs 2 days for the TA group (p=0.0006). The probability of recurrent gout flares was 3.7% with canakinumab 150 mg vs. 45.4% with TA 8 weeks post treatment, a relative risk reduction of 94% (p=0.006). Serious AEs occurred in 2 patients receiving canakinumab (appendicitis and carotid artery stenosis) and 1 receiving TA (cerebrovascular disorder). Investigator's reported these events as not study drug related. There were no discontinuations due to AEs. Conclusion: Canakinumab 150 mg provided faster onset and superior pain relief compared to TA for acute flares in gouty arthritis patients refractory to or contraindicated to standard treatments. The 150 mg dose of canakinumab prevented recurrence of gout flares with a relative risk reduction compared to TA of 94% at 8 weeks post-dose, and was well tolerated.